Update on staging and surgical treatment options for esophageal cancer
- PMID: 21487832
- DOI: 10.1007/s11605-011-1515-9
Update on staging and surgical treatment options for esophageal cancer
Abstract
Introduction: Esophageal cancer remains a challenging clinical problem, with overall long-term survivorship consistently at a level of approximately 30%. The incidence of esophageal cancer is increasing worldwide, with the most dramatic increase being seen with respect to esophageal adenocarcinoma.
Discussion: Pretreatment staging accuracy has improved with the utilization of CT and PET scans, as well as endoscopic ultrasound and endoscopic mucosal resection. In an increasing percentage of patients, endoscopic techniques are being utilized in selected patients for the treatment of high-grade dysplasia in Barrett's and intramucosal cancer. Surgery remains the treatment of choice in all appropriate patients with invasive and locoregional esophageal cancer, although multimodality therapy is now used in most patients with stage II or stage III disease.
Conclusion: Outcomes for esophagectomy have been dominated by concerns regarding high mortality and morbidity; however, mortality rates associated with esophageal resection have dramatically decreased, especially in high-volume specialty centers. This manuscript highlights some of the evolutionary issues associated with staging and endoscopic and surgical treatments of Barrett's and esophageal cancer.
Similar articles
-
Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies.J Thorac Cardiovasc Surg. 2014 Feb;147(2):765-71: Discussion 771-3. doi: 10.1016/j.jtcvs.2013.10.003. Epub 2013 Dec 4. J Thorac Cardiovasc Surg. 2014. PMID: 24314788
-
Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer.Surg Endosc. 2010 Jun;24(6):1380-6. doi: 10.1007/s00464-009-0783-x. Epub 2009 Dec 24. Surg Endosc. 2010. PMID: 20033712
-
Treatment of Barrett's esophagus with high-grade dysplasia.Expert Rev Anticancer Ther. 2009 Mar;9(3):303-16. doi: 10.1586/14737140.9.3.303. Expert Rev Anticancer Ther. 2009. PMID: 19275509 Review.
-
Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?World J Gastroenterol. 2017 Dec 14;23(46):8193-8199. doi: 10.3748/wjg.v23.i46.8193. World J Gastroenterol. 2017. PMID: 29290655 Free PMC article.
-
Esophageal cancer: an update.Int J Surg. 2010;8(6):417-22. doi: 10.1016/j.ijsu.2010.06.011. Epub 2010 Jun 30. Int J Surg. 2010. PMID: 20601255 Review.
Cited by
-
Chylothorax after esophagectomy for cancer: impact of the surgical approach and neoadjuvant treatment: systematic review and institutional analysis.Surg Endosc. 2013 Oct;27(10):3530-8. doi: 10.1007/s00464-013-2991-7. Epub 2013 May 25. Surg Endosc. 2013. PMID: 23708712
-
Computed tomography volumetry of esophageal cancer - the role of semiautomatic assessment.BMC Med Imaging. 2019 Feb 15;19(1):17. doi: 10.1186/s12880-019-0317-5. BMC Med Imaging. 2019. PMID: 30767773 Free PMC article.
-
Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study.Int J Clin Oncol. 2013 Apr;18(2):214-9. doi: 10.1007/s10147-011-0362-8. Epub 2011 Dec 23. Int J Clin Oncol. 2013. PMID: 22193638
-
Esophageal organoids: applications and future prospects.J Mol Med (Berl). 2023 Aug;101(8):931-945. doi: 10.1007/s00109-023-02340-5. Epub 2023 Jun 29. J Mol Med (Berl). 2023. PMID: 37380866 Review.
-
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.BMC Cancer. 2014 Jan 2;14:2. doi: 10.1186/1471-2407-14-2. BMC Cancer. 2014. PMID: 24383423 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical